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THIOL-CONTAINING COMPOUNDS FOR 
THE REMOVAL OF ELEMENTS FROM 
TISSUES AND FORMULATIONS THEREFOR 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
This application is a continuation-in-part of US. patent 
application Ser. No. 12/892,464, ?led on Sep. 28, 2010, 
Which in turn is a continuation of international patent appli 
cation no. PCT/US10/50512, ?led on Sep. 28, 2010 and 
claiming the bene?t of priority in US. Provisional Applica 
tion Ser. Nos. 61/246,278, 61/246,282 and 61/246,360, all 
three ?led on Sep. 28, 2009, the entire disclosures of each of 
Which are incorporated herein in their entirety. 
FIELD OF THE INVENTION 
The present invention relates to compounds utiliZed in 
covalent binding to a Wide range of metals and main group 
elements, and more speci?cally to sulfur-containing ligands 
and the utiliZation of such to remove contaminants from 
solids, liquids and gases. 
BACKGROUND OF THE INVENTION 
Heavy metal and main group element pollution is an exist 
ing and groWing WorldWide problem. During the past feW 
decades, federal and state governments have instituted envi 
ronmental regulations to protect the quality of surface and 
ground Water from contaminants. In response to these regu 
latory requirements, numerous products have been developed 
to precipitate contaminants from surface Water, ground Water 
and soil. Examples of compositions and methods utiliZed in 
precipitating metals from Water and soil are detailed in US. 
Pat. No. 6,586,600, the entire disclosure of Which is hereby 
incorporated by reference. 
There are numerous industrial and environmental situa 
tions Where ligands capable of binding metals and main group 
elements can be utiliZed for remediation purposes. For 
example, Waste Water issuing from Waste treatment facilities, 
chlor-alkali industries, metal ?nishing industries and certain 
municipal land?lls often present contamination problems. 
Similarly, the metal content of Water exiting both functional 
and abandoned mines is a signi?cant environmental issue in 
geographical areas With a heavy mining industry. Soil and 
surface Waters located in areas near natural gas pump houses 
suffer a similar metal contamination problem. Gasses emitted 
from coal-?red poWer plants and the incineration of munici 
pal and medical Waste contain mercury. Thus, there is a need 
for ligands capable of binding and removing metals and main 
group elements from gasses, aqueous and non-aqueous solu 
tions and solid substrates. 
It is knoWn in the art to use sulfur-containing compounds to 
bind heavy metals. For example, Thio-Red® is a chemical 
reagent used for precipitating divalent heavy metals from 
Water. This product is a complex aqueous solution of sodium 
(With or Without potassium) thiocarbonate, sul?des, and other 
sulfur species. Thio-Red® ultimately removes Cu, Hg, Pb, 
and Zn from aqueous solutions through the formation of 
metal sul?des (i.e. CuS, HgS, PbS, and ZnS), rather than 
metal thiocarbonates. Sodium and potassium dialkyldithio 
carbamates such as HMP-2000®, are also Widely used as 
metal precipitants. HoWever, the limited ability of most 
reagents presently used on a commercial basis to form stable, 
covalent bonds With heavy metals is a major concern for 
remediation applications. Reagents that lack su?icient or 
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metal-speci?c binding sites may produce metal precipitates 
that are unstable over time and under certain pH conditions. 
Such unstable precipitates may release bound metal back into 
the environment, thereby proving unsatisfactory as treatment 
or remediation agents. Further, these reagents may form 
simple metal sul?des Which bacteria are capable of methylat 
ing (in the case of Hg, forming the Water-soluble cation, 
MeHg”). Accordingly, there is a need for ligands Which not 
only bind metals and main group elements, but also hind these 
elements in such a manner as to form stable, insoluble pre 
cipitates Which retain the contaminant element(s) over a Wide 
range of environmental conditions and over extended periods 
of time. 
Likewise, it is knoWn to use a variety of chelators for 
chelation therapy of metals. Many studies today re?ect the 
increasing exposure of the population to mercury and other 
toxic heavy metals. Examples of currently approved binders 
for treating heavy metal toxicity such as mercury toxicity are 
dimercaptopropanesulfonate (DMPS) and dimercaptosuc 
cinic acid (DMSA), Which Were introduced during World War 
II to combat industrial exposure to heavy metals. Conven 
tional compounds such as DMPS and DMSA, While often 
referred to as “chelators,” are not truly chelators in the chemi 
cal sense of the Word. This is because there is insuf?cient 
space betWeen the sulfurs on adjacent carbon atoms to alloW 
a large metal atom to bind to both sulfurs at the same time, 
Which is a requirement for forming a true “chelate.” Rather, 
DMPS and DMSA form bound sandWich complexes With 
metal, Where for example tWo binder molecules bind to a 
single mercury atom. This provides a Weaker attachment than 
Would be the case With a true chelator, Which Would form tWo 
bonds betWeen the thiol (iSH) groups and the HG2+. Also, 
based on their negatively charged properties, binders like 
DMSA, DMPS and EDTA have a non-speci?c attraction for 
all metal ions, including the essential metals Ca“, Mg“, 
Mn2+, etc. The rapid excretion of these binders from the body 
through the urine can have the negative effect of depleting the 
body of these essential metals. Deaths have occurred by 
essential metal depletion by charged binding compounds dur 
ing a process called chelation therapy, and this medical treat 
ment must therefore be done by an experienced physician. 
Heavy metals such as mercury are typically lipid-soluble 
or can pass through the cell membrane via native divalent 
metal ion carriers (e. g. for Ca“, Mg2+) as the M2+ form, and 
may therefore concentrate intracellularly and more so in the 
adipose, or fatty, tissue or in other tissues high in lipid content, 
including Without limitation the central nervous system. 
Indeed, mercury and other heavy metals preferentially parti 
tion to and concentrate in the hydrophobic aspects of mam 
mals, ?sh, and the like, such as fatty tissues, cell membranes, 
lipid-containing areas of the interior of a cell, and the like. 
Thus, the currently available, approved heavy metal bind 
ers have several disadvantages With regard to their overall 
chemical nature that could be improved on by the synthesis of 
better-designed, true chelators that have safer excretory prop 
erties such as higher a?inity for the metals and/ or main group 
elements and excretion through the feces instead of the urine. 
Such better-designed, true chelators Would desirably be 
uncharged, lipid-soluble or hydrophobic compounds, or 
alternatively convertible from Water soluble (for suitability 
for delivery via the bloodstream) to lipid-soluble compounds 
in the body, to alloW them to partition into the fatty (hydro 
phobic) tissues Where the mercury or other heavy metal bur 
den is primarily located. Further, such chelators Would pos 
sess loW or, better yet, no observable toxicity to mammals 
alone in the absence of heavy metal expo sures. They Would be 
true chelators that Would bind heavy metals and main group 
US 8,575,218 B2 
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elements exceptionally tightly, preventing toxic effects and 
also preventing release or concentration in toxic form in any 
organ of the body. Still further, desirably the chelators Would 
be excreted through the biliary transport system of the liver 
into the feces instead of through the kidneys (a very sensitive 
organ to heavy metal exposure) and into the urine. Still yet 
further, it Would be desirable to provide improved chelators 
Which readily convert betWeen Water-soluble and lipid 
soluble forms, alloWing excretion by the desired route, i.e., 
via the kidney for the Water-soluble form and via the biliary 
transport system of the liver into the feces for the lipid-soluble 
form. 
SUMMARY OF THE INVENTION 
In one embodiment, chelate ligands are of the general 
formula: 
O 
Y 
where R1 is selected from a group including benZene, pyri 
dine, pyridin-4-one, naphthalene, anthracene, phenanthrene 
and alkyl groups, R2 is independently selected from a group 
including hydrogen, alkyls, aryls, a carboxyl group, carboxy 
late esters, organic groups and biological groups, R3 is inde 
pendently selected from a group including alkyls, aryls, a 
carboxyl group, carboxylate esters, organic groups and bio 
logical groups, X is independently selected from a group 
including hydrogen, lithium, sodium, potassium, rubidium, 
cesium, francium, alkyls, aryls, a carboxyl group, carboxylate 
esters, cysteine, homocysteine, glutathione, lipoic acid, dihy 
drolipoic acid, thiophosphate, N-acetyl cysteine, mercap 
toacetic acid, mercaptopropionic acid, y-glutamyl cysteine, 
phytochelatins, thiolsalicylate, organic groups and biological 
groups, n independently equals 1-10, m:1-6, Y is indepen 
dently selected from a group including hydrogen, polymers, 
silicas and silica supported substrates, and Z is selected from 
a group including hydrogen, alkyls, aryls, a carboxyl group, 
carboxylate esters, a hydroxyl group, NH2, HSO3, halogens, 
a carbonyl group, organic groups, biological groups, poly 
mers, silicas and silica supported substrates, With the proviso 
that when R1 represents an alkyl group, at least one X cannot 
simultaneously represent hydrogen. 
In another aspect, the present invention relates to methods 
of removing metals and/or main group elements from a start 
ing material. The methods comprise contacting a starting 
material With an effective amount of a sulfur-containing che 
late ligand as described above for a suf?cient time to form a 
stable ligand-metal and/or ligand-main group element com 
plex(es), said metal and/or main group element complex(es) 
remaining essentially irreversibly bound to said ligand over a 
range of acidic and basic pH values. 
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In another aspect, the present invention relates to methods 
of removing metals and/ or main group elements from a lipid 
containing tissue in a human and/or animal body. The meth 
ods comprise intravenously delivering an amount of a sulfur 
containing chelate ligand as described above to a lipid 
containing tissue in a body, forming a ligand-metal and/or 
ligand-main group element complex(es), and excreting the 
complex(es) from the body. We have observed that certain 
prior art uncharged, hydrophobic compounds, such as those 
disclosed in Us. Pat. No. 6,586,600 to AtWood et al., have 
exceptionally loW toxicity When injected or ingested by test 
animals. Disadvantageously, the Water-insolubility of these 
hydrophobic compounds makes them poor candidates for 
intravenous applications. Intravenous (IV) application has 
the advantage of speed of general delivery and the ability to 
treat an unconscious patient. Therefore, in the present disclo 
sure, analogs of uncharged, non-toxic chelators are described 
Which may initially be provided as charged, Water soluble 
compounds. These Water-soluble compounds are converted 
in the blood to uncharged lipid soluble compounds Which can 
enter the membranes and other hydrophobic aspects of cells 
and tissues, and even cross the blood brain barrier. 
Further, the present disclosure provides uncharged, non 
toxic lipid soluble analogs that can be converted by intracel 
lular enZymes once internaliZed into Water soluble chelators. 
These same compounds can be treated externally With 
enZymes (esterases) to make them Water soluble for IV appli 
cations. This may be especially useful if treatment is required 
that does not enter cells or cross the blood brain barrier and 
still retain high heavy metal and/ or main group element a?in 
ity. 
In one embodiment of this aspect, the described chelators 
are thiol/thiolate compounds including an aromatic ring 
structure, further including additional functional groups on 
the organic ring structure and/ or on the pendent thiol chains. 
A representative structure for the compounds is set forth 
beloW. In that structure, Z andY may be a variety of combi 
nations of organic, organometallic and inorganic groups, 
including Without limitation OH, COOH, NH2, HSO3, halo 
gens, and the like. X may be one or more of hydrogen, 
halogens, organic groups providing thioethers and related 
derivatives, or metals selected Without limitation from the 
Group 1 and 2 elements recited in the Periodic Table of the 
Elements, or may include charged molecules having a termi 
nal sulfhydryl include Without limitation glutathione, cys 
teine, homocysteine, lipoic acid, dihydrolipoic acid, thio 
phosphate, N-acetyl mercaptoacetic acid, 
mercaptopropionic acid, y-glutamyl cysteine, phytochelatins, 
thiolsalicylate, and the like. The reference character n may 
represent any integer from 1-10. Other aromatic groups con 
templated include naphthalene, anthracene, phenanthrene, 
and the like as set forth above. 
cysteine, 
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-continued 
O 
I m 
Y 
Still further, particular aspects of the present disclosure are 
directed to pharmaceutically effective amounts and formula 
tions of such chelators for removing metals and/or main 
group elements from human and/or animal body tissues, such 
as for ameliorating oxidative stress, treating heavy metal or 
other toxicity, raising in vivo glutathione levels, as dietary 
supplements, and the like. The pharmaceutically effective 
amount of the compounds in question may be administered in 
any appropriate manner including Without limitation oral 
administration, transdermal administration, nasal administra 
tion, intravenous administration, suppository, and others. 
As a dietary supplement, methods for such supplementa 
tion include orally administering betWeen about 0.5 and about 
40.0 mg of compound per kilogram of the mammal’s today 
body Weight per day, although due to the lack of toxicity 
higher dose levels are acceptable. Optionally, the compounds 
may be administered With one or more additional antioxi 
dants or chelators. Exemplary supplemental antioxidants 
include Without intending any limitation vitamin E, vitamin 
D, cysteine, cystine, glutathione, lipoic acid, and combina 
tions. 
In methods of removing heavy metals or other toxins from 
mammalian tissues, the compound may be administered in 
amounts of betWeen about 0.5 mg and about 60.0 mg per 
kilogram of total body Weight per day, although due to the 
lack of toxicity of the compounds higher doses may be appro 
priate. 
Likewise, in methods for ameliorating oxidative stress, 
suitable administration routes include administering orally, 
transdermally, nasally, intravenously, by suppository, or other 
appropriate routes. The compounds may be administered in 
amounts of betWeen about 0.5 mg and about 100.0 mg per 
kilogram of total body Weight per day, although due to the 
lack of toxicity of the compounds higher doses may be appro 
priate, such as in cases of acute toxicity or high oxidative 
stress. The compounds may be used to treat oxidative stress 
resulting from virtually any source or cause, including With 
out limitation heavy metals, drugs such as acetaminophen, 
xenobiotics, aging, infection, physical injury, and disease. 
Other aspects of the present invention Will become appar 
ent to those skilled in this art from the folloWing description 
Wherein there is shoWn and described exemplary embodi 
ments of this invention. As it Will be realiZed, the invention is 
capable of further embodiments and its several details are 
capable of modi?cation in various, obvious aspects Without 
departing from the invention. Accordingly, the draWings and 
descriptions Will be regarded as illustrative in nature and not 
as restrictive. 
BRIEF DESCRIPTION OF THE FIGURES 
The folloWing detailed description of speci?c embodi 
ments of the present disclosure can be best understood When 
read in conjunction With the folloWing draWings, in which: 
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FIG. 1 shoWs the Weight loss results of a thermogravime 
teric analysis on Si60 from a temperature range of 30° C. to 
1000° C. With a temperature increase of 20° C./min and a How 
rate of 1 10/ 55 mmHg (inlet/outlet pressure) performed in air 
atmosphere; 
FIG. 2 shoWs the Weight loss results of a thermogravime 
teric analysis on SiNH2 from a temperature range of 30° C. to 
1000° C. With a temperature increase of 20° C./min and a How 
rate of 1 10/ 55 mmHg (inlet/outlet pressure) performed at air 
atmosphere; 
FIG. 3 shoWs the Weight loss results of a thermogravime 
teric analysis on SiAB9 produced from a ?rst experimental 
procedure from a temperature range of 30° C. to 1000° C. 
With a temperature increase of 20° C./min and a How rate of 
110/55 mmHg (inlet/outlet pressure) performed at air atmo 
sphere; 
FIG. 4 shoWs the Weight loss results of a thermogravime 
teric analysis on SiAB9 produced from a second experimen 
tal procedure from a temperature range of 30° C. to 1000° C. 
With a temperature increase of 20° C./min and a How rate of 
110/ 55 mmHg (inlet/outlet pressure) performed at air atmo 
sphere; 
FIG. 5 shoWs the chemical structures of various hydropho 
bic chelators according to the present invention, Which are 
converted to hydrophilic chelators Within the microenviron 
ment; and 
FIGS. 6a and 6b shoW the chemical structures of various 
chelators according to the present invention, Which may be 
introduced into a body in a hydrophilic state, reduced to a 
hydrophobic state in the body for partitioning into lipid-rich 
areas, and subsequently enZymatically returned to a hydro 
philic state iii vivo. 
DETAILED DESCRIPTION OF ILLUSTRATIVE 
EMBODIMENTS 
As summarized above, the present invention relates to 
novel sulfur-containing chelate ligands Which bind metals 
and/or main group elements resulting in ligand-metal and/or 
ligand-main group element complex(es) Which remain stable 
at a Wide range of pH values. In forming the ligand-metal 
and/or ligand-main group element complex(es), the novel 
ligands are capable of forming covalent bonds With the metals 
and/or main group elements that may not be broken under 
most acidic or basic conditions. The ligands of the present 
invention are suitable for binding metals and/or main group 
elements Which are in or are capable of being placed in a 
positive oxidation state, including, but not limited to, yttrium, 
lanthanum, hafnium, vanadium, chromium, uranium, manga 
nese, iron, cobalt, nickel, palladium, platinum, copper, silver, 
gold, Zinc, cadmium, mercury, lead, tin and the like. The 
ligands of the present invention are also suitable for binding 
main group elements Which are in or are capable of being 
placed in a positive oxidation state, hereinafter de?ned as 
including gallium, indium, thallium, boron, silicon, germa 
nium, arsenic, antimony, selenium, tellurium, polonium, bis 
muth, molybdenum, thorium, plutonium and the like. 
In one aspect, the present invention relates to chelate 
ligands consisting of an organic group from Which depends at 
least one alkyl chain that terminates in a sulfur-containing 
group. The chelate ligands may be of the general formula: 
US 8,575,218 B2 
where R1 may be selected from a group comprising organic 
groups that include, but are not limited to, benzene, pyridine, 
pyridin-4-one, naphthalene, anthracene, phenanthrene and 
alkyl groups such as (CH2)y Where y:2-8, R2 may be inde 
pendently selected from a group comprising hydrogen, 
alkyls, aryls, a carboxyl group, carboxylate esters, other 
organic groups that include, but are not limited to, acyls and 
amides, and biological groups that include, but are not limited 
to, amino acids and proteins such as cysteine, R3 may be 
independently selected from a group comprising alkyls, aryls, 
carboxyl groups, carboxylate esters, other organic groups that 
include, but are not limited to, acyls and amides, and biologi 
cal groups that include, but are not limited to, proteins and 
amino acids such as cysteine, X may be independently 
selected from a group comprising hydrogen, lithium, sodium, 
potassium, rubidium, cesium, francium, alkyls, aryls, a car 
boxyl group, carboxylate esters, cysteine, homocysteine, glu 
tathione, lipoic acid, dihydrolipoic acid, thiophosphate, 
N-acetyl cysteine, mercaptoacetic acid, mercaptopropionic 
acid, y-glutamyl cysteine, phytochelatins, thiolsalicylate, 
organic groups and biological groups, n may independently 
equal 1-10, m may equal 1-6, Y may be independently 
selected from a group comprising hydrogen, polymers, silicas 
and silica supported substrates, and Z may be independently 
selected from a group comprising hydrogen, alkyls, aryls, a 
carboxyl group, carboxylate esters, a hydroxyl group, NH2, 
HSO3, halogens, a carbonyl group, organic groups, biological 
groups, polymers, silicas and silica supported substrates. In 
some embodiments n may independently equal to 1-6 or 1-4. 
In some embodiments m may equal 1-2 or 4-6, and in certain 
interesting embodiments, m equals 2. In embodiments Where 
mz2, the sulfur atoms of multiple alkyl chains may share a 
single X constituent. In such embodiments, X may be inde 
pendently selected from a group comprising beryllium, mag 
nesium, calcium, strontium, barium and radium. 
While not Wishing to be bound by any particular theory, it 
is believed that the stability of the metal and/or main group 
element complexes formed through utilization of the ligands 
of the present invention is derived from the multiple interac 
tions betWeen the metal and/or main group element atoms and 
the sulfur and/or nitrogen atoms on the ligand. Accordingly, it 
is believed that the sulfur and/or nitrogen atoms form a mul 
tidentate bonding arrangement With a metal and/ or main 
group element atom. In embodiments of ligands that include 
multiple alkyl chains (i.e., mz2), a metal and/or main group 
element atom may be bound through interactions With the 
multiple sulfur and/or nitrogen atoms of the ligand. In 
embodiments of ligands that include a single alkyl chain (i.e., 
m:1), a metal and/or main group element atom may be bound 
through interactions With the sulfur and/ or nitrogen atoms of 
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multiple ligands. HoWever, metal and/or main group element 
atoms may also be bound by the sulfur and/ or nitrogen atoms 
of several ligands that include multiple alkyl chains. Accord 
ingly, the ligands may form metal and/ or main group element 
complexes though the interactions betWeen the metal and/or 
main group element atoms and the sulfur and/or nitrogen 
atoms of a single ligand, as Well as form polymeric metal 
and/or main group element complexes through the interac 
tions betWeen the metal and/ or main group element atoms and 
the sulfur and/or nitrogen atoms of multiple ligands. 
The compounds may be bonded to supporting material Y at 
R3 . Depending on the value of m, Y may comprise polymers, 
silicas, silica supported substrates or hydrogen. If m:1, then 
Y may be selected from a group comprising hydrogen, poly 
mers, silicas and silica supported substrates, alumina and 
other metal oxide materials. If m>1, then each Y may be 
independently selected from a group comprising hydrogen, 
polymers, silicas, silica supported substrates, alumina and 
other metal oxide materials. Thus, Where m>1 , the compound 
may bond to supporting material Y at a single R3 , at all of the 
R3 groups, or any combination thereof. Furthermore, Y may 
comprise ?ltration beads or be otherWise embedded or 
impregnated in a ?ltration medium. For example, in one 
embodiment, Y may comprise polystyrene beads such that the 
sulfur-containing compounds are supported on the polysty 
rene beads for the ?ltration of contaminants. 
In one useful embodiment, the chelate ligands may be of 
the general formula: 
where R1 may be selected from a group comprising benZene, 
pyridine, naphthalene, anthracene, phenanthrene and alkyl 
groups, R2 may be independently selected from a group com 
prising hydrogen, alkyls, aryls, a carboxyl group, carboxylate 
esters, organic groups and biological groups, R3 may be inde 
pendently selected from a group comprising alkyls, aryls, a 
carboxyl group, carboxylate esters, organic groups and bio 
logical groups, X may be independently selected from a 
group comprising hydrogen, lithium, sodium, potassium, 
rubidium, cesium, francium, cysteine and glutathione, n inde 
pendently equals 1-10, m:1-6, and Y may be independently 
selected from a group comprising hydrogen, polymers, silicas 
and silica supported substrates, With the proviso that when R1 
represents an alkyl group, at least one X cannot simulta 
neously represent hydrogen. 
In another useful embodiment, chelate ligands may be of 
the genera formula: 
0 
Y 
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where R1 may be selected from a group comprising benzene, 
pyridine, naphthalene, anthracene, phenanthrene and alkyl 
groups, R2 may be independently selected from a group com 
prising hydrogen, alkyls, aryls, a carboxyl group, carboxylate 
esters, organic groups and biological groups, R3 may be inde 
pendently selected from a group comprising alkyls, aryls, a 
carboxyl group, carboxylate esters, organic groups and bio 
logical groups, X may be independently selected from a 
group comprising hydrogen, lithium, sodium, potassium, 
rubidium, cesium, francium, cysteine and glutathione, n inde 
pendently equals 1-10, m:1-6, andY may be independently 
selected from a group comprising hydrogen, polymers, silicas 
and silica supported substrates. 
In another useful embodiment, the present invention 
relates to chelate ligands consisting of an organic structure 
from Which depend tWo alkyl chains terminating in sulfur 
containing groups. The chelate ligands may be of the general 
formula: 
CH 
( 2% ACHZ). 
S—X X—S 
Z 
I l 
OYRYO 
/N\R2 R2/N 
(CHm WCH». 
where R1 may be selected from a group comprising benZene, 
pyridine, pyridin-4-one, naphthalene, anthracene, phenan 
threne and alkyl groups, R2 may be independently selected 
from a group comprising hydrogen, alkyls, aryls, a carboxyl 
group, carboxylate esters, organic groups and biological 
groups, R3 may be independently selected from a group com 
prising alkyls, aryls, a carboxyl group, carboxylate esters, 
organic groups and biological groups, X may be indepen 
dently selected from a group comprising hydrogen, lithium, 
sodium, potassium, rubidium, cesium, francium, cysteine and 
glutathione, n independently equals 1-10, Y may be indepen 
dently selected from a group comprising hydrogen, polymers, 
silicas and silica supported substrates, and Z may be indepen 
dently selected from a group comprising hydrogen, alkyls, 
aryls, a carboxyl group, carboxylate esters, a hydroxyl group, 
NH2, HSO3, halogens, a carbonyl group, organic groups, 
biological groups, polymers, silicas and silica supported sub 
strates. 
In another useful embodiment, the present invention 
relates to chelate ligands consisting of an organic structure 
from Which depend tWo alkyl chains terminating in sulfur 
containing groups. However, in this embodiment, the tWo 
sulfur atoms of the tWo alkyl chains share one X constituent. 
The chelate ligands may be of the general formula: 
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Z 
| 
OYRYO 
/N N 
(CH2)n 
ACHZ). 
where R1 may be selected from a group comprising benZene, 
pyridine, pyridin-4-one, naphthalene, anthracene, phenan 
threne and alkyl groups, R2 may be independently selected 
from a group comprising hydrogen, alkyls, aryls, a carboxyl 
group, carboxylate esters, organic groups and biological 
groups, R3 may be independently selected from a group com 
prising alkyls, aryls, a carboxyl group, carboxylate esters, 
organic groups and biological groups, X may be selected 
from a group comprising beryllium, magnesium, calcium, 
strontium, barium and radium, n independently equals 1-10, 
Y may be independently selected from a group comprising 
hydrogen, polymers, silicas and silica supported substrates, 
and Z may be independently selected from a group compris 
ing hydrogen, alkyls, aryls, a carboxyl group, carboxylate 
esters, a hydroxyl group, NH2, HSO3, halogens, a carbonyl 
group, organic groups, biological groups, polymers, silicas 
and silica supported substrates. 
In another useful embodiment, the present invention 
relates to chelate ligands consisting of a ring structure from 
Which depend tWo alkyl chains terminating in sulfur-contain 
ing groups. The chelate ligands may be of the general for 
mula: 
o 0 
Y— R3 N R3 —Y or 
\ R2 R2 / 
ml)" ACHZ). 
s — X — 
o o 
N 
/ / 
(CH2). R2 R2 \CH». 
Y— R3 s — X X — 8 R3 Y 
Where R2 may be independently selected from a group com 
prising hydrogen, alkyls, aryls, a carboxyl group, carboxylate 
esters, organic groups and biological groups, R3 may be inde 
pendently selected from a group comprising alkyls, aryls, a 
carboxyl group, carboxylate esters, organic groups and bio 
US 8,575,218 B2 
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logical groups, X may be independently selected from a 
group comprising hydrogen, lithium, sodium, potassium, 
rubidium, cesium, francium, cysteine and glutathione, n inde 
pendently equals 1-10, andY may be independently selected 
from a group comprising hydrogen, polymers, silicas and 5 
silica supported substrates. As disclosed in US. Pat. No. 
12 
6,586,600, chelate ligands of the above general formula, 
Wherein the R3 groups (as Well as the R2 groups) comprise 
hydrogen, both n equal 1, and bothY comprise hydrogen, may 
be referred to as “B9.” 
In another useful embodiment of B9, the chelate ligands 
are of the formula: 
0 o 
N N 
o 
<CH2>n\S s/cHm O OH \ or 
/ s 
o rlr s 
N NH2 
)K/N \H 
HO H\ 
o N o N O 
/ y H 0 
on 
o 
HZN 
on 
o 
/N N\(CH ) 
(CI-12);’! )2 n O 
o T | OH 
0 ill s 
N NH2 
)K/N \ HO H 
H 
o N o \N O 
H/ (\d 
on 
o 
HZN 
on 
65 Where n independently equals 1-10. Chelate ligands of this 
general formula may be referred to as “glutathione B9” or 
abbreviated to “GB9.” 
US 8,575,218 B2 
13 
In one useful embodiment of GB9, the chelate ligand is of 
the formula: 
NH HN 
j o 
S S 
/ \S 
o H s 
| N 
N \H 
Ho H\ 
o N o N O 
/ 
H 0 
0H 
0 
HZN 
oH 
0&0 
NH HN 
o 
S S 
/ \S 
o H s 
| N 
N \H 
Ho H\ 
O N N o 
/ 
H 0 
0H 
0 
HZN 
oH 
In another useful embodiment, the present invention 
relates to chelate ligands consisting of a ring structure from 
Which depend tWo alkyl chains terminating in sulfur-contain 
ing groups. In this embodiment the tWo sulfur atoms of the 
tWo alkyl chains share one X group. The chelate ligands may 
be of the general formula: 
(CH2) 
” \ s X — s or 
50 
65 
Where R2 may be independently selected from a group com 
prising hydrogen, alkyls, aryls, a carboxyl group, carboxylate 
esters, organic groups and biological groups, R3 may be inde 
pendently selected from a group comprising alkyls, aryls, a 
carboxyl group, carboxylate esters, organic groups and bio 
logical groups, X may be selected from a group comprising 
beryllium, magnesium, calcium, strontium, barium and 
radium, n independently equals 1-10, andY may be indepen 
US 8,575,218 B2 
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dently selected from a group comprising hydrogen, polymers, 
silicas and silica supported substrates. 
In another useful embodiment, the chelate ligands are of 
the formula: 
where R1 may be selected from a group comprising benzene, 
pyridine, naphthalene, anthracene, phenanthrene and alkyl 
groups, R2 may be independently selected from a group com 
prising alkyls, aryls, a carboxyl group, carboxylate esters, 
organic groups and biological groups, X may be indepen 
dently selected from a group comprising hydrogen, lithium, 
sodium, potassium, rubidium, cesium, francium, cysteine, 
and glutathione, n independently equals 1-10, andY may be 
independently selected from a group comprising hydrogen, 
polymers, silicas and silica supported substrates. Chelate 
ligands of these general formulas may be referred to as “acid 
B9” or abbreviated to “AB9.” 
In one useful embodiment of AB9, the chelate ligands are 
of the formula: 
I 
o R o 
N N 
o \R2 R2/ 
1 
OY RYO 
N N 
/ \ / \ 
(CH2). R2 R2 (CH2). 
where R1 may be selected from a group comprising benZene, 
pyridine, naphthalene, anthracene, phenanthrene and alkyl 
groups, R2 may be independently selected from a group com 
prising hydrogen, alkyls, aryls, a carboxyl group, carboxylate 
esters, organic groups and biological groups, X may be inde 
pendently selected from a group comprising beryllium, mag 
nesium, calcium, strontium, barium and radium, n indepen 
dently equals 1-10, and Y may be independently selected 
from a group comprising hydrogen, polymers, silicas and 
silica supported substrates. 
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In another useful embodiment of AB9, the chelate ligands 
are of the formula: 
Where R2 may be independently selected from a group com 
prising hydrogen, alkyls, aryls, a carboxyl group, carboxylate 
esters, organic groups and biological groups, n independently 
equals 1-10, and Y may be independently selected from a 
group comprising hydrogen, polymers, silicas and silica sup 
ported substrates. 
In another useful embodiment of AB9, the chelate ligands 
are of the formula: 
0 O 
O O 
NH HN 
Y—O O—Y or 
S—H H—S 
O O 
NH HN 
O O 
S—H H—S 
Y—O O—Y 
Where Y may be independently selected from a group com 
prising hydrogen, polymers, silicas and silica supported sub 
strates. 
US 8,575,218 B2 
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In another useful embodiment of AB9, the chelate ligands 
are of the formula: 
O O 
O O 
N N 
Y — o \ R2 R2 / o — Y 
O 
(CH2)n\ S /(CH2)n O 
S \ OH or 
/ S 
O fll S 
N NH2 
)K/N \H 
HO H\ 
o N o N O 
/ 
H O 
OH 
O 
HZN 
OH 
O O 
N N O 
2 z / \ 
O (CH2)n R R (CH2)n 
S O 
Y—O s O_Y 
I O 
OH 
O fll S S 
)K/N N NHZ HO \ 
H H 
O N O 
/ \ N o 
H 
O 
0 OH 
HZN 
OH 
Where R2 may be independently selected from a group com- group comprising hydrogen, polymers, silicas and silica sup 
prising hydrogen, alkyls, aryls, a carboxyl group, carboxylate 65 ported substrates. Chelate ligands of this general formula may 
esters, organic groups and biological groups, nindependently be referred to as “glutathione AB9” or abbreviated to 
equals 1-10, and Y may be independently selected from a “GAB9.” 
US 8,575,218 B2 
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In one useful embodiment of GAB9, the chelate ligand is of 
the formula: 
#QYO O 
NH HN 
O 
O 
S O Y O S _ 
Y—O / \S O 
0 III S OH or 
N N NH HOJK/ \ 2 
H H 
O N O 
/ \N o 
H 
O 
O OH 
HZN 
OH 
O O 
O 0 
NH HN 
Y—O O—Y 
S O 
S 
/ \S O 
O III S OH 
N N NH HOJK/ \ 2 
H H 
O N O 
/ \N o 
H 
O 
O OH 
HZN 
OH 
WhereY may be independently selected from a group com- Where PS may be polystyrene or a co-polymer containing 
prising hydrogen, polymers, silicas and silica supported sub- 50 polystyrene- In one even more Particular embodiment, PS 
snares, may be chloromethylated polystyrene-co-diVinylbenZene 
(2% DVB, 200-400 mesh). 
In one particular embodiment of the material supported 
AB9, the material may be deriVatiZed prior to the addition of 
AB9, or its equivalent, providing a structure With the formula: 
In another useful embodiment of AB9, the AB9 may be 
material supported With a structure of: 
O O 
O #QY O 60 
\ NH HN 
O OH 
SH HS 65 
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Alternatively, AB9 may be loaded onto amine functional 
iZed silica (Silica-NH2). In one exemplary embodiment, 
Silica-NH2, produced by binding y-aminopropyltriethoxysi 
lane on silica-60 (Si60), may be re?uxed in a solution of AB9 
in ethanol producing a structure of the formula: 
O 0 
SH HS 
In an alternative preparation, SiNH2 may be treated With 
AB9 in the presence of dicyclohexylcarbodiimide (DCC) to 
facilitate the coupling of the AB9 to the amine of the PS. 
In another useful embodiment, the chelate ligands are of 
the formula: 
1 
o R o 
O Y O 
N N 
Y/\O \R2 R2/ O/\Y or 
CH 
( 2k ACHZ). 
Y Y 
where R1 may be selected from a group comprising benZene, 
pyridine, naphthalene, anthracene, phenanthrene and alkyl 
groups, R2 may be independently selected from a group com 
prising hydrogen, alkyls, aryls, a carboxyl group, carboxylate 
esters, organic groups and biological groups. X may be inde 
pendently selected from a group comprising hydrogen, 
lithium, sodium, potassium, rubidium, cesium, francium, 
cysteine and glutathione, n independently equals 1-10, andY 
is a methyl group. Chelate ligands of these general formulas 
may be referred to as “methyl ester AB9” or abbreviated to 
“MEAB9.” 
In one useful embodiment of MEAB9, the chelate ligands 
are of the formula: 
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-continued 
R1 
0y YO 
N N 
\ / \ 
<CHZ>K R2 R2 (CH2). 
O O 
K W 
Y Y 
where R1 may be selected from a group comprising benZene, 
pyridine, naphthalene, anthracene, phenanthrene and alkyl 
groups, R2 may be independently selected from a group com 
prising hydrogen, alkyls, aryls, a carboxyl group, carboxylate 
esters, organic groups and biological groups, X may be inde 
pendently selected from a group comprising beryllium, mag 
nesium, calcium, strontium, barium and radium, n indepen 
dently equals 1-10, andY is a methyl group. 
In another useful embodiment of MEAB9, the chelate 
ligands are of the formula: 
0 o 
o o 
N N 
/ Y/\O \R2 R2 O/\Y or 
(CH2)n (CH2)n 
SH HS/ 
0 o 
N N 
/ / \ 
<CH2>n R2 R2 (CH2). 
0 0 
SH HS 
(0 OH 
Y Y 
Where R2 may be independently selected from a group com 
prising hydrogen, alkyls, aryls, a carboxyl group, carboxylate 
esters, organic groups and biological groups, n independently 
equals 1-10, andY is a methyl group. 
In another useful embodiment of MEAB9, the chelate 
ligands are of the formula: 
0 O 
O O 
NH HN 
YAQKK fkOAY or 
SH HS 



























